A Recombinant Vaccine for Tuberculosis

In a phase IIa trial, vaccination with MVA85A was well tolerated and induced T-cell responses in individuals with HIV infection, Mtb infection, or both.

Infection with Mycobacterium tuberculosis (Mtb) confers a 10% lifetime risk for developing tuberculosis (TB) in otherwise healthy people; HIV infection may increase such risk >10-fold. The live, attenuated bacille Calmette-Guérin vaccine protects against TB during infancy, but its usefulness in older individuals is uncertain.

MVA85A is a recombinant strain of modified vaccinia that expresses the Mtb antigen 85A. In a small phase I study, it was shown to be immunogenic and safe in patients with latent tuberculosis infection (LTBI; Am J Respir Crit Care Med 2009; 179:724). Now, in an open-label, phase IIa trial conducted in South Africa, researchers have investigated the safety and immunogenicity of this vaccine in patients with HIV infection,…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

A Recombinant Vaccine for Tuberculosis

Topics

Reviewing Author